tbuckley/cabot-search huggingface dataset:
Evaluation of Early Complications Related to De Novo Cardioverter Defibrillator Implantation
Authors: Douglas S. Lee, Andrew D. Krahn, Jeffrey S. Healey, David Birnie, Eugene Crystal, Paul Dorian, Christopher S. Simpson, Yaariv Khaykin, Douglas Cameron, Amir Janmohamed, Raymond Yee, Peter C. Austin, Zhongliang Chen, Judy Hardy, Jack V. Tu
Journal: Journal of the American College of Cardiology (2010)

This study examined the predictors of early complications after defibrillator implantation. Although implantable cardioverter-defibrillators are widely used, predictors of procedural complications and the consequences of these events have not been determined. In a prospective, multicenter, population-based clinical outcomes registry of all newly implanted defibrillator patients at 18 centers in Ontario, Canada, we examined 45-day complications and all-cause mortality from February 2007 to May 2009. Complications were determined longitudinally and were categorized as direct implant-related or indirect events. Among 3,340 patients (mean age 63.8 ± 12.5 years, 78.5% men), major complications occurred in 4.1% of de novo procedures. Compared with those undergoing a single-chamber device, implantation of a cardiac resynchronization defibrillator (adjusted hazard ratio [HR]: 2.17, 95% confidence interval [CI]: 1.38 to 3.43, p < 0.001) or dual-chamber device (adjusted HR: 1.82, 95% CI: 1.19 to 2.79, p = 0.006) was associated with increased risk of major complications. Major complications were increased in women (adjusted HR: 1.49, 95% CI: 1.02 to 2.16, p = 0.037) and when left ventricular end-systolic dimension exceeded 45 mm (adjusted HR: 1.54, 95% CI: 1.08 to 2.20, p = 0.018). Major complications (excluding death) occurring early after defibrillator implantation were associated with increased adjusted risk of subsequent death up to 180 days after defibrillator implant (adjusted HR: 3.70, 95% CI: 1.64 to 8.33, p = 0.002). Direct implant-related complications were associated with increased risk of early death (adjusted HR: 24.89, p = 0.01), whereas indirect clinical complications conferred increased risk of near-term death (adjusted HR: 12.35, p < 0.001) after defibrillator implantation. Complications after de novo defibrillator implantation were strongly associated with device type. Major complications were associated with increased risk of mortality.
Abstract P189: Method of Cold Saline Storage for Prehospital Induced Hypothermia
Authors: Mitch Kampmeyer, Clifton W Callaway
Journal: Circulation (2008)

Recent research supports the use of cold IV fluid as a method for initiating therapeutic hypothermia in post-cardiac arrest resuscitation. However, prehospital care programs employing this treatment have encountered various difficulties. Barriers to prehospital induced hypothermia protocols include the lack of effective or economically reasonable methods to maintain cold saline in the field. Objective. Determine the time that a standard commercial cooler can maintain two 1-liter normal saline solution (NSS) bags below 4°C in 3 different environments. Methods. Environments simulating an ambulance compartment were created for the experiment. NSS temperatures were continuously recorded inside a standard commercial cooler with or without ice packs (IPs) under one of three scenarios: ambient room temperature (25°C) without (IPs), ambient room temperature with IPs and 50°C ambient temperature with IPs. Four trials under each condition were performed. Time to warm to 4°C was compared using Kaplan-Meier log rank test. Results. In a room temperature environment with IPs, the NSS warmed to 4°C in a mean interval of 29 hrs 53 mins versus in ambient room temperature without IPs (1 hr 21 mins) versus in constant hot environment of 50°C with IPs (10 hrs 50 mins). A significant difference was found between the three environments (log-rank =17.90, dF =2, p =0.0001). Conclusions. Low technology methods in the form of a cooler and IPs can provide cold NSS storage for longer than a full 24 hour shift in a room temperature ambulance. In hot ambient conditions, 4°C NSS can be maintained for nearly 11 hours using this method. This model exhibits an economical, easily deployable cold saline storage unit.
Abstract 15751: Estimation of Pulmonary Arterial Pressure in Subjects with Pulmonary Hypertension by Configuration of Right Ventricle Obtained by Electrocardiogram Gated Conventional Scan in 320 Slice CT
Authors: Toshihiko Sugiura, Nobusada Funabashi, Nobuhiro Tanabe, Masae Uehara, Hiroyuki Amano, Yukiko Matsuura, Naoko Kawata, Miyako S Kitazono, Issei Komuro, Kouichiro Tatsumi
Journal: Circulation (2010)
Possible synergism between fluoxetine and lithium in refractory depression
Authors: H G Pope, S L McElroy, R A Nixon
Journal: American Journal of Psychiatry (1988)

Five depressed patients who had shown no improvement with trials of antidepressants from several chemical families, including fluoxetine, responded when lithium was given in conjunction with fluoxetine. Lithium augmentation of fluoxetine may represent a useful strategy in refractory depression.
Use of bortezomib to overcome the poor prognosis of t(4;14), but not del(17p), in young patients with newly diagnosed multiple myeloma.
Authors: H. Avet-Loiseau, P. Moreau, C. Mathiot, C. Charbonnel, T. Facon, M. Attal, C. Hulin, G. Marit, S. Minvielle, J. Harousseau
Journal: Journal of Clinical Oncology (2010)

8113 Background: Translocation t(4;14)(p16;q32) has been associated with a poor outcome in multiple myeloma. This poor prognosis has been identified both in patients treated with melphalan-prednisone (MP) and in those treated with high-dose melphalan after a VAD induction. For instance, in 100 patients with t(4;14) treated with VAD and MEL200, the median PFS and OS were 21 months and 41 months, respectively, as compared to 37 months and 65 months for patients lacking the t(4;14) (Moreau et al., Leukemia 2007). Some preliminary studies have suggested that bortezomib was able to overcome the poor prognosis of the translocation in elderly patients treated with MP-bortezomib (San Miguel et al., NEJM 2008). Methods: In order to address this important question, we analyzed 507 patients treated in the IFM, according to the IFM-2005-01 trial, arm B: induction with 4 cycles of bortezomib (Velcade)/dexamethasone (VD), followed by one or two courses of high-dose melphalan (MEL200). Results: A translocation t(4;14) was observed in 106 of these 507 patients treated with VD, whereas del(17p) was found in 60 patients. Of note, 10 patients presented both the t(4;14) and the del(17p). The median PFS was 28 and 35 months, in patients with or without the t(4;14), respectively (p<0.02). At 3 years, 73% of the patients with t(4;14) were still alive, as compared to 89% of the patients lacking the translocation (p=0.002). For comparison, the OS results were respectively 48% (patients with t(4;14)) and 73% (patients lacking the translocation) in patients treated with a VAD induction within the same period. Thus, it seems that VD is able to significantly overcome the poor prognosis of t(4;14). We also looked at the prognostic value of del(17p) in this series of patients treated with VD. In contrast to the t(4;14) situation, VD was enable to rescue patients with del(17p) (same PFS and OS for patients treated with VD than for those treated with a VAD induction). Conclusions: Thus, this study (by far the largest so far reported) shows that VD as induction before intensification is able to improve the prognosis of patients with t(4;14), but not of those with del(17p). Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Janssen-Ortho
Abstract 4602: Complete Revascularization in Patients With Multivessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Meta Analysis
Authors: Sripal Bangalore, Sabrina Sawhney, Scott Kinlay, Bernard J Gersh, David P Faxon
Journal: Circulation (2009)

Background: Complete revascularization with coronary artery bypass graft surgery (CABG) provides greater benefits than incomplete revascularization, in patients with multivessel coronary artery dis...
A non myeloablative regimen for allografting high-risk patients: Low toxicity, stable engraftment without GVHD, disease control and potential for GVL with adoptive immunotherapy.
Authors: P D Kottaridis, R Chakraverty, D W Milligan, S Chakrabarti, S Robinson, R Chopra, R Pettengell, J Marsh, P Mahendra, S Schey, G H Morgan, C Williams, G Hale, H Waldmann, D C Linch, S Devereux, A H Goldstone, S Mackinnon
Journal: Blood (1999)
Characterization of chronic hypersensitivity pneumonitis and evaluation of its predictive factors – Retrospective study
Authors: Rui Rolo, Antόnio Morais, Natália Melo, Patrícia Mota, José Miguel Pereira, Maria Antόnia Vasconcelos, Susana Guimarães, Conceição Souto-Moura
Journal: European Respiratory Journal (2011)

Background:  A percentage of patients with hypersensitivity pneumonitis (HP), despite appropriate therapeutic measures, evolves to chronicity.   Objective:  Characterization of clinical presentation, lung function, radiological, histological and bronchoalveolar lavage fluid (BALF) features of patients with chronic HP and evaluation of its potential predictive factors.   Material and methods:  Retrospective analysis of patients with HP diagnosed according to the criteria of Schuyler and Cormier. CT scans were classified according to Sahin et al score. Patients with chronic evolution of HP were compared to those with disease regression.   Results:  Were included 70 patients. Average age was 50 years; 65.7% females and 84.3% non-smokers. Avian proteins (81.4%) and moldy cork dust (7.1%) were the most common etiological antigens. Twenty-nine (41%) patients progressed to chronicity. Restrictive ventilatory syndrome was more severe in the group of patients with chronic evolution with lower FVC (p   Presence of reticular and honeycombing patterns were associated with evolution to chronicity (p  No statistically significant differences between groups concerning BALF cellularity.  In 20 patients (28.6%) surgical lung biopsy was performed. Pathology evaluation revealed the expected association of honeycombing with the evolution to chronicity (p = 0.004).   Conclusion:  Lung function measurements seemed to be those who better predict the evolution of HP.
TIM-3, a Leukemia Stem Cell Marker, Plays a Role In Leukemic Transformation Through Autocrine Stimulatory Signaling By Its Ligand, Galectin-9
Authors: Yoshikane Kikushige, Junichiro Yuda, Takahiro Shima, Toshihiro Miyamoto, Koichi Akashi
Journal: Blood (2013)
Abstract 3433: Cardiac Myocyte-specific Caveolin-3 Overexpression Modulates ERK/EGFR Signaling and Attenuates Cardiac Hypertrophy
Authors: Yousuke T Horikawa, Yasuo M Tsutsumi, Hemal H Patel, Paul A Insel, David M Roth
Journal: Circulation (2008)

Introduction: The localization and organization of signaling molecules involved in cardiac hypertrophy and remodeling are poorly understood. Caveolae, invaginations of the sarcolemma and enriched in the protein caveolin (Cav), localize signaling molecules involved in cardiac hypertrophy and remodeling. Cav-3, which is unique to myocyte caveolae, inhibits extracellular signal-regulated kinase (ERK) phosphorylation in vitro and binds the epidermal growth factor (EGF) receptor. We hypothesized that cardiac myocyte-specific overexpression of Cav-3 (Cav-3 OE) would modulate ERK signaling via direct interaction and alteration in EGF receptor signaling and would attenuate cardiac hypertrophy. Methods: Transgenic mice with cardiac myocyte-specific Cav-3 OE (generated using an α-myosin heavy chain promoter) and littermate controls (C) were subjected to transverse aortic constriction (TAC) for 4 weeks. Echocardiography, histology and molecular analysis were performed. Cardiac myocytes were isolated and stimulated with phenylephrine (Phe) and EGF to assess ERK activity via activation of Gq and EGF receptors, respectively. Results: Cav-3OE mice had reduced heart weight/tibia length ratio post-TAC compared to C (9.9±0.8 vs. 12.9±0.5 mg/mm; n=8; P&lt;0.05) and decreased myocyte cross sectional area compared to C (203±8 vs. 327±17 μm2/cell; n=7; P&lt;0.001). Cav-3 OE and C mice had similar fractional shortening (FS) pre-TAC but post-TAC, Cav-3 OE had greater FS compared to C (29.2±3.2 vs. 20.8±3.0%; n=8–9; P&lt;0.05). Fibrosis, as assessed by trichrome stain, was decreased in Cav-3 OE compared to C mice. Post-TAC, pERK expression in cardiac homogenates was decreased in Cav3-OE mice vs. C. In vitro, pERK had, similar expression in the two groups in response to Phe, but pERK was expressed at higher levels in Cav3-OE myocytes in response to EGF receptor simulation. Conclusion: These results show that cardiac-specific Cav-3 OE alters ERK/EGFR signaling in cardiac myocytes, producing a phenotype with blunted cardiac hypertrophy and preserved cardiac function post-TAC. This suggests that cardiac myocyte-specific Cav-3 OE may provide a novel approach to improve cardiac function in pathological cardiac hypertrophy and remodeling. This research has received full or partial funding support from the American Heart Association, AHA Western States Affiliate (California, Nevada &amp; Utah).
A Prospective Randomized Multicenter Comparison of Balloon Angioplasty and Infrapopliteal Stenting With the Sirolimus-Eluting Stent in Patients With Ischemic Peripheral Arterial Disease
Authors: Dierk Scheinert, Konstantinos Katsanos, Thomas Zeller, Renate Koppensteiner, Philip Commeau, Marc Bosiers, Hans Krankenberg, Iris Baumgartner, Dimitris Siablis, Johannes Lammer, Mariella Van Ransbeeck, Ayesha C. Qureshi, Hans-Peter Stoll
Journal: Journal of the American College of Cardiology (2012)
Abstract 16950: Sphingosine-1-Phosphate is Thromboxane-dependently Released from Platelets and Modulates Chemotaxis of Human Monocytes
Authors: Amin Polzin, Andreas Böhm, Thomas Ulrych, Anke C Rosenkranz, Thomas Hohlfeld, Karsten Schrör, Bernhard H Rauch
Journal: Circulation (2010)

Sphingosine-1-phosphate (S1P) is a sphingosine-derived lipid signaling molecule and an important mediator of vascular homeostasis. Upon vascular injury, S1P is released from platelets by thrombin. The underlying mechanisms and functional consequences are to date incompletely understood. Here, we describe that the release of S1P from human platelets induced after activation of the protease-activated receptor-1 (PAR-1) by thrombin dependent on thromboxane (TX) formation. Platelet-derived S1P modulates human monocyte migration which is attenuated after inhibition of TX formation. S1P was detected by mass spectrometry and by thin layer chromatography in [3H]sphingosine-labeled platelets. Human peripheral blood monocytes were isolated by ficoll gradient centrifugation and cleared from contaminating leukocytes by antibody-coated beads. Migration was determined in modified Boyden chamber assays. RNA interference was used to knock down S1P receptor expression. Release of S1P was stimulated about 5 fold (0.3±0.1 vs. 1.6±0.5 nmol/1x106 platelets) by the PAR-1-activating-peptide (SFLLRN, 100 μmol/L). Acetylsalicylic acid (ASA) and also the reversible cyclooxygenase inhibitors diclofenac and ibuprofen suppressed S1P release. Oral ASA (100 mg over 3 days) attenuated S1P release from platelets in healthy volunteers which was paralleled by inhibition of TX formation. S1P release was increased by the thromboxane receptor (TXR) agonist U46619, and inhibited by the TXR antagonist ramatroban. After incubation of human peripheral blood monocytes with supernatants from stimulated platelets for 24 hours, chemotaxis towards serum (10%) or monocyte chemotactic protein-1 (MCP-1, 50 ng/mL) was increased about 3-fold compared to supernatants from resting platelets. This effect was inhibited when platelets were previously treated with ASA. Gene-specific knockdown suggest that the S1P receptor-1 (S1P1) and S1P3 mediate this modulation of monocyte chemotactic responses. These data suggest that S1P release from platelets after thrombin receptor activation requires TX synthesis. Inhibition of S1P release may be involved in the anti-inflammatory actions of ASA, for example by affecting recruitment of monocytes to sites of vascular injury.
Tet induced in vitro model of MUC1 expression
Authors: Zulfiqar G. Gulzar, Hanna M. Romanska, Paul Abel, Gordon Stamp, El-Nasir M. A. Lalani
Journal: Cancer Research (2005)

Proc Amer Assoc Cancer Res, Volume 46, 2005

5674 

Over expression of MUC1 mucin characterizes an invasive and metastatic phenotype of various adenocarcinomas. Its functions are considered to be mediated via its large ectodomain characterized by 20 amino acid variable number of tandem repeat (TR) and signal transduction via the cytoplasmic tail (CT). It has been hypothesized that the length of the VNTR is inversely proportional to E-cadherin mediated cell-cell interaction. The aim of our study was to establish a tetracycline based (Tet-Off) inducible MUC1 expression system in cell lines devoid of MUC1 protein that would enable examination of a relationship between the VNTR length and its function in a number of cell types. Five epithelial cell lines, PC-3, HCT 116, Caco-2, A-375 and MDCK were screened for surface and intracellular expression of MUC1 using RT-PCR, immunohistochemistry, FACS analysis and western blotting. Two of the cell lines, HCT 116 and MDCK, were found to fulfil the requirements of the study (MUC1-, α+, β+, γ+ catenin and E-cadherin+). Six MUC1 plasmid vectors with 0, 4, 8, 14, 19 and 42 TRs were generated. Selected cell lines were transfected with tet operative (tetO) and tet response plasmid (pTRE2) containing MUC1 cDNA. A double vector tetracycline inducible expression system was established and shown to be functional in both HCT116 and MDCK cell lines. Cells transfected with MUC1 cDNA containing 0 and 42 TRs expressed both intracellular and surface MUC1 mucin and responded to tetracycline induced on/off switch. This system may have a wide range of applications. In particular, an easy switch of MUC1 expression may prove very useful in investigation of a role of MUC1in the modulation of cell-cell and cell-ECM interactions in both in vitro and in vivo experimental models.
Abstract 14185: Heart Failure Occurring at any Time During Hospitalization is Associated with Higher Mortality in Non-ST Elevation-Acute Coronary Syndromes
Authors: Maria Cecilia Bahit, Renato D Lopes, Robert Clare, Karen S Pieper, L. Kristin Newby, Frans Frans Van de Werf, Paul W Armstrong, Kenneth W Mahaffey, Robert A Harrington, E. Magnus Ohman, Rafael Diaz, Harvey D White, Adrian F Hernandez, Lars Wallentin, Robert M Califf, Christopher B Granger
Journal: Circulation (2011)

Background:  Heart failure (HF) is a frequent complication of ACS and is associated with poor prognosis. However, most studies only included patients with ST elevation myocardial Infarction (STEMI). Thus, we aim to describe the occurrence and timing of HF complicating non-ST elevation acute coronary syndrome (NSTE-ACS), identify predictors of admission and in-hospital new onset HF, and assess the association of HF with post-discharge mortality at 30 day.   Methods:  We examined combined patient-level data from 46,519 NSTE-ACS patients enrolled in 7 clinical trials: GUSTO IIb, PURSUIT, PARAGON A, PARAGON B, ESSENCE, SYNERGY and EARLY-ACS. Patients with cardiogenic shock or Killip class IV were excluded. Admission HF was defined as Killip Class II or III and patients with in-hospital HF had no admission HF and had a complication of HF or pulmonary edema prior discharge. Logistic regression models were performed to assess predictors of HF and the association of 30-day mortality after hospital discharge with HF, adjusting for baseline variables.   Results:  From the NSTE-ACS patients, 4,910 (10.5%) had HF on admission, 1,194 (2.6%) developed HF during hospitalization, and 40,415 (86.9%) had no HF at any time. Patients presenting with HF or developing HF during hospitalization tended to be older and more likely female compared with those with no heart failure. Increased age, female sex, current smoker, higher HR, DM, lower SBP, hypertension, prior MI, and ST changes were strongly associated with HF. Patients with HF on admission and during hospitalization had higher risk of post-discharge death at 30 days when compared with patients without heart failure (Table).   Conclusion:  In this large patient population of NSTE-ACS, occurrence of heart failure at any time was associated with increased risk of death within 30 days of hospital discharge. Research targeting new strategies to prevent and to manage HF after NSTE-ACS is needed. Table. Post-discharge 30-day mortality
Abstract 13504: Mortality in STEMI Patients Undergoing Inter-Hospital Transfer for Primary PCI in Massachusetts
Authors: Murtuza J Ali, Zoran S Nedeljkovic, Katya Zelevinsky, Ann Lovett, Sharon-Lise T Normand, Alice K Jacobs
Journal: Circulation (2010)

Background: Primary percutaneous coronary intervention (PCI) is the preferred reperfusion strategy for ST-elevation myocardial infarction (STEMI) if delivered in a timely fashion. To study the impa...
Studies on the Etiology of Goiter Including Graves' Disease.
Authors: David Marine
Journal: Annals of Internal Medicine (1930)

Article1 November 1930Studies on the Etiology of Goiter Including Graves' Disease.DAVID MARINEDAVID MARINESearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-4-5-423 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIt is scarcely necessary to repeat to this audience the usual expression of feeling greatly honored at being invited to discuss certain features of my work in the University where I spent 15 pleasant years and where foundations of anything I have done in medicine were laid. It is necessary, however, out of fairness, to explain to this audience that much of the work I shall talk about tonight is the combined outcome of the friendly discussions, criticisms and hard work of men well honored and now living in Cleveland. I have particularly in mind the names of Lenhart, Stewart... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New York*McBride Lecture, Western Reserve University, delivered Nov. 11, 1929. Nextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byContribution a l'etude experimentale de l'exophtalmie endocrinienneSome Unsolved Problems Concerning the Pathogenesis of Human Deficiency Disease SyndromesThe Chemistry and Physiology of the Thyroid HormoneKropf und Jodmangeltheorie 1 November 1930Volume 4, Issue 5Page: 423-432KeywordsEmotionsEtiology ePublished: 1 December 2008 Issue Published: 1 November 1930 PDF downloadLoading ...